APA

Stintzing S., Miller-Phillips L., Modest D. P., Fischer von Weikersthal L., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S., Heintges T., Kahl C., Seipelt G., Kullmann F., Stauch M., Scheithauer W., Held S., Moehler M., Jagenburg A., Kirchner T., Jung A. & Heinemann V. (20170821). Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. : European journal of cancer (Oxford, England : 1990).

Chicago

Stintzing S, Miller-Phillips L, Modest D P, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A and Heinemann V. 20170821. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. : European journal of cancer (Oxford, England : 1990).

Harvard

Stintzing S., Miller-Phillips L., Modest D. P., Fischer von Weikersthal L., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S., Heintges T., Kahl C., Seipelt G., Kullmann F., Stauch M., Scheithauer W., Held S., Moehler M., Jagenburg A., Kirchner T., Jung A. and Heinemann V. (20170821). Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. : European journal of cancer (Oxford, England : 1990).

MLA

Stintzing S, Miller-Phillips L, Modest D P, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A and Heinemann V. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. : European journal of cancer (Oxford, England : 1990). 20170821.